Nijmegen

• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Pending
  2025-523481-24-00 5 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 5 Non-Small Cell Lung Cancer
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• Healing Diabetic Foot Ulcers with Semaglutide Pending
  2025-524738-24-00 6 Diabetic foot ulcer
• An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospit … Pending
  2025-525053-39-00 5 Coronary artery disease
• A clinical study investigating modafinil for the treatment of severe fatigue in patients with inflammatory bowel disease (MODIFI-IBD trial) Pending
  2026-525163-41-00 10 Inflammatory bowel disease
• PLUTO Pending
  2026-525211-14-00 4 HIV-1
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting
  2025-524265-24-00 5 2026-05-21 Dyslipidemia at High to Very High Cardiovascular Risk
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• A Study in Pediatric Participants with Congenital Adrenal Hyperplasia Recruiting
  2024-519578-38-00 10 2026-03-30 Classic congenital adrenal hyperplasia
• A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy Recruiting
  2024-515635-30-00 3 2026-03-24 Coagulopathy
• KHENERFIN Recruiting
  2025-522361-30-00 5 2026-03-17 Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G variant and A
• A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting
  2024-516476-15-00 9 2026-03-04 Advanced gastrointestinal stromal tumor (GIST)
• A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections Recruiting
  2024-516216-16-00 5 2026-02-13 Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lo
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• EASE SBS 5 (Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS) Recruiting
  2024-512486-14-00 5 2026-01-22 Short Bowel Syndrome
• A Global Phase 3 Open-Label Extension Study to Assess AOC 1001 in Patients with DM1 Recruiting
  2025-520766-22-00 5 2026-01-21 Myotonic Dystrophy Type 1
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer

Showing 49–72 of 568 trials